Fundraising Fox
/Companies
Sign in

Memo Therapeutics AG

acquired by Clementia

Zurich, CH · Founded 2012 · 36 employees on LinkedIn · 12 known investors

Find your way into Memo Therapeutics AG

Sign up to find every way you can get introduced to Memo Therapeutics AG

  • Your email: who you already know at Memo Therapeutics AG, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Memo Therapeutics AG team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Memo Therapeutics develops therapeutic antibodies targeting viral infections to improve treatment outcomes for patients with conditions like BKPyV infection in kidney transplant recipients and oncological viral diseases. The company is a late-stage biotech enterprise collaborating with academic institutions and pharmaceutical partners to advance its pipeline.

BiotechMedical Devices

Investors · 12

Pureos Bioventures✓ confirmed by Memo Therapeutics AGPfäffikon

How we know: Pureos Bioventures's portfolio page · the company's own site · a partner's Signal profile · memo-therapeutics.com · Not right? Tell us

Ysios Capital✓ confirmed by Memo Therapeutics AGBarcelona · $5.4M – $21.6M

How we know: Ysios Capital's portfolio page · the company's own site · memo-therapeutics.com · the VCSheet dataset · Not right? Tell us

Adjuvant Capitallisted by Adjuvant CapitalNew York · $10M – $25M

How we know: Adjuvant Capital's portfolio page · a partner's Signal profile · memo-therapeutics.com · Not right? Tell us

Fresenius Medical Care Ventureslisted by Fresenius Medical Care VenturesBad Homburg

How we know: Fresenius Medical Care Ventures's portfolio page · memo-therapeutics.com · Not right? Tell us

Verve Ventureslisted by Verve VenturesZürich · $300K – $2.2M

How we know: Verve Ventures's portfolio page · memo-therapeutics.com · Not right? Tell us

redalpinereportedZug · $108K – $2.2M

How we know: the VCSheet dataset · Not right? Tell us

Also in the syndicate · 5

GF GroupRed AlpineSchroders CapitalSwisscantoVesalius Biocapital

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Memo Therapeutics AG Increase Series C Financing to CHF 45 Million - Memo Therapeuticsmemo-therapeutics.com · May 2024Memo Therapeutics AG Raises CHF 25 Million Series C Financing to Complete Phase II Clinical Development of AntiBKV for BKV Infection in Renal Transplant Patients - Memo Therapeuticsmemo-therapeutics.com · Nov 2023

Frequently asked questions

What does Memo Therapeutics AG do?
Memo Therapeutics develops therapeutic antibodies targeting viral infections to improve treatment outcomes for patients with conditions like BKPyV infection in kidney transplant recipients and oncological viral diseases. The company is a late-stage biotech enterprise collaborating with academic institutions and pharmaceutical partners to advance its pipeline.
Who are Memo Therapeutics AG's investors?
Memo Therapeutics AG's investors include Kurma Partners, Pureos Bioventures, Ysios Capital, Adjuvant Capital, Fresenius Medical Care Ventures, Verve Ventures, redalpine.
Who acquired Memo Therapeutics AG?
Memo Therapeutics AG was acquired by Clementia.
Where is Memo Therapeutics AG headquartered?
Memo Therapeutics AG is headquartered in Zurich, CH.